Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
The Lancet. Neurology|February 21, 2006
MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up studyTijmen Korteweg, Mar Tintoré, Bernard Uitdehaag, et al.
Journal of Neuro-Oncology|November 1, 2016
Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohortKatrina A Morris, John F Golding, Claire Blesing, et al.
Archives of Disease in Childhood|March 15, 2018
Diagnosis of sporadic neurofibromatosis type 2 in the paediatric populationGeetha Anand, Grace Vasallo, Maria Spanou, et al.
Journal of Medical Genetics|August 16, 2015
Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patientsAdam Hexter, Adrian Jones, Harry Joe, et al.
Frontiers in Psychiatry|April 5, 2021
Failure of Healthcare Provision for Attention-Deficit/Hyperactivity Disorder in the United Kingdom: A Consensus StatementSusan Young, Philip Asherson, Tony Lloyd, et al.
Neurosurgery|October 4, 2017
Malignant Peripheral Nerve Sheath Tumors are not a Feature of Neurofibromatosis Type 2 in the Unirradiated PatientAndrew T King, Scott A Rutherford, Charlotte Hammerbeck-Ward, et al.
Pageof 4